Mineralocorticoid receptor antagonists can not only lower blood pressure, but also improve insulin sensitivity, relieve oxidative stress and reduce the inflammatory response of MetS, which could eventually prevent the occurrence of cardiovascular disease (26). This evidence concerns the gene INS and metabolic syndrome.